The Evidence Base for Commercial Probiotics
Cut through marketing claims. We catalogue clinical trials, strain-level efficacy, and survivability data to help practitioners and formulators navigate the probiotic landscape.
Browse the Strain Library
Why Strain Specificity Matters
Specific Question Answered: Does it matter which Lactobacillus I take? Yes, absolutely. The core failing of modern probiotic marketing is species-level generalization. Efficacy is entirely dependent on the specific strain. For example, Lactobacillus rhamnosus GG has over 1,000 published studies demonstrating specific immunological benefits, whereas an unspecified L. rhamnosus isolate may have none.
Our methodology insists on clinical validation at the strain level, tracking CFUs at end-of-shelf-life, and validating delivery mechanisms against gastric acid degradation.
Common Mistakes in Probiotic Selection
- Buying based on total CFU count rather than strain specificity.
- Ignoring storage requirements (e.g., leaving lyophilized powders in a humid bathroom).
- Assuming a multi-strain blend is superior to a targeted single strain without clinical evidence.
Efficacy Thresholds by Strain
A summary of minimum effective dosages based on peer-reviewed clinical data. This is a living table updated quarterly.
| Strain Designation | Primary Indication | Demonstrated Efficacy (CFU) | Clinical References |
|---|---|---|---|
| Lactobacillus rhamnosus GG (ATCC 53103) | Pediatric acute infectious diarrhea | ≥ 10 × 109 | Szajewska et al. (2013) |
| Bifidobacterium infantis 35624 | IBS symptom relief | 1 × 108 | Whorwell et al. (2006) |
| Saccharomyces boulardii CNCM I-745 | Prevention of antibiotic-associated diarrhea | 5 × 109 (approx 500mg) | McFarland (2010) |
| Lactobacillus plantarum 299v | IBS (abdominal pain reduction) | 10 × 109 | Ducrotté et al. (2012) |
Table 1.1: Efficacy thresholds are derived directly from the protocols of successful randomized controlled trials (figures dated as of Q3 2024). Formulations providing lesser amounts must be viewed with skepticism.
Interactive Tools for Formulators
We build tools to model degradation and compare strain efficacy. These tools process data entirely in your browser.
CFU Degradation Modeler
Estimate the viable count at end-of-shelf-life based on initial overage, temperature, and AW.
Strain Comparison Matrix
Side-by-side analysis of clinical backing, survivability, and patent status.
Clinical Dose Converter
Translate clinical trial dosages (mg vs CFU) into practical formulation requirements.
Frequently Asked Questions
What is the difference between a strain and a species?
Lactobacillus is a genus. rhamnosus is a species. GG is the strain. Think of it like Dog (Genus) -> Retriever (Species) -> Golden (Strain). The specific traits that provide clinical benefits belong to the strain.
Do I always need 50 Billion CFU?
No. B. infantis 35624 is clinically effective at 1 Billion CFU. Taking 50 Billion of an unstudied strain will yield worse results than 1 Billion of a specific, targeted strain.
Next Steps
Begin by exploring our Strain Library to understand the clinical backing behind specific isolates, or review our Product Analysis to see how commercial formulations stack up. If you are formulating a product, our Advisory Services team can assist.
Explore Bisria: Home, Strain Library, BB536 Profile, LGG Profile, B. infantis Profile, S. boulardii Profile, Lp299v Profile, Clinical Research, IBS Management, AAD Prevention, Pediatric Diarrhea, Product Roundups, CFU Calculator, Strain Matrix, Dose Converter, Acid Survival, Cost Analyzer, Pediatric Dosing, Prebiotic Matrix, Patent IP, Diet Interactions, Delivery Scoring, Strain Quiz, Storage Analysis, Advisory, About Us, Contact Us.